Epidyolex 100 mg/ml oral solution clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex (EpiCom)
This study looks at how a medicine called Epidyolex affects behaviour and other common issues in children and young people (1-65 years old) with Tuberous Sclerosis Complex (TSC) who experience seizures. It's an add-on treatment.
For: Tuberous Scerlosis ComplexPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures
This study looks at a medicine called Epidyolex for young children with Dravet Syndrome, Tuberous Sclerosis Complex, or Lennox-Gastaut Syndrome. It checks if the medicine is safe, how much stays in the body, and if it helps reduce seizures. This is a big final-stage study.
For: Dravet Syndrome · Tuberous sclerosis complex · Lennox-Gastaut SyndromeItaly · Spain - Ongoing, recruitingPhase II and Phase III (Integrated)
Cannabidiol for treatment of non-affective psychosis and cannabis use
This study looks at how a cannabis-based medicine (cannabidiol) might help people with certain mental health conditions (psychosis) who also use cannabis. It wants to see if this medicine can reduce their symptoms and help them cut down or stop cannabis use.
For: Lifetime cannabis use · Non-affective psychosisDenmark - AuthorisedTherapeutic exploratory (Phase II)
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
This study looks at whether a cannabis-based medicine called Epidyolex can help children and teenagers with severe learning difficulties who hurt themselves. We want to see if it reduces how often they self-injure over about two months.
For: Children and adolescents with severe neurodevelopmental disordersFrance - AuthorisedTherapeutic confirmatory (Phase III)
Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series
This study looks at how well a medicine called Epidyolex (which has CBD in it) helps with behaviour problems in people with particular conditions like Tuberous Sclerosis, Sanfilippo, and Fragile X syndrome. It checks if it improves things like irritability.
For: Tuberous Sclerosis Complex (TSC) · Sanfilippo syndrome · Fragile X syndrome (FXS)Netherlands